Geriatric Assessment for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how androgen deprivation therapy (hormone therapy) affects frailty and serious side effects in men over 65 with advanced prostate cancer. Researchers will collect blood samples, survey responses, and data from wearable devices over five years. Eligible participants are men diagnosed with prostate cancer that has spread and are planning to start hormone therapy soon. This trial does not suit those who have already received certain prostate cancer treatments or have uncontrolled illnesses like poorly managed diabetes or high blood pressure. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Do I need to stop my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.
What prior data suggests that androgen deprivation therapy is safe for men over 65 with prostate cancer?
Previous studies have shown that androgen deprivation therapy (ADT) effectively treats prostate cancer by lowering male hormone levels that can promote cancer growth. Research indicates that ADT reduces cancer markers, such as prostate-specific antigen, in over 90% of patients, suggesting the treatment is generally well-tolerated and effective for many.
However, like any treatment, ADT can cause side effects. Some studies report that about 43% of patients experience sexual problems, which occur more frequently than in those not receiving the treatment. Awareness of these side effects is important for discussing expectations and management strategies with a doctor.
Overall, ADT remains a common and effective treatment for prostate cancer, but discussing potential side effects with a healthcare provider is crucial for managing them.12345Why are researchers excited about this trial?
Researchers are excited about the Geriatric Assessment and Technology Evaluation in Prostate Cancer trial because it explores how technology can improve the treatment process for older patients with prostate cancer. Unlike traditional treatments that focus solely on medication or surgery, this approach integrates digital tools to assess and manage the unique needs of geriatric patients. The trial aims to find out if personalized technology can enhance the effectiveness of existing treatments, improve patient quality of life, and tailor care to individual health profiles. By focusing on these aspects, the trial could pave the way for more comprehensive and patient-centered care options in prostate cancer treatment.
What evidence suggests that androgen deprivation therapy might be an effective treatment for prostate cancer?
Research has shown that hormone therapy, known as androgen deprivation therapy (ADT), effectively treats prostate cancer, especially when it has metastasized. Studies demonstrate that ADT can significantly help prevent further spread of the cancer. For instance, combining ADT with radiotherapy has improved survival rates. One study found that using ADT for longer periods led to better survival outcomes. These findings suggest that ADT plays a crucial role in managing advanced prostate cancer.26789
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Study Visits
Participants attend 5 study visits in the first year to give blood samples, answer survey questions, and use a wearable device
Follow-up
Participants are monitored for safety and effectiveness after study visits, with regular doctor visits and medical record reviews
What Are the Treatments Tested in This Trial?
Interventions
- Androgen Deprivation Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor
Citations
Effects of Androgen Deprivation Therapy on Prostate Cancer ...
We analysed the effectiveness of androgen deprivation therapy (ADT) for localised prostate cancer among patients, defined by the relative ...
Balancing Hormone Therapy: Mitigating Adverse Effects of ...
Treatment advances including ADT have led to improvements in PCa management and survival, with trials reporting median survival of over 6 years ...
Articles Duration of androgen deprivation therapy with ...
Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy.
Androgen deprivation therapy use and duration with ...
The addition of ADT to radiotherapy significantly improved metastasis-free survival (HR 0·83 [95% CI 0·77–0·89], p<0·0001), as did adjuvant ADT ...
Association of Gleason Grade With Androgen Deprivation ...
Conclusions and Relevance These data suggest that prolonged durations of ADT improve survival outcomes in both GG 4 disease and GG 5 disease, ...
Androgen deprivation therapy for prostate cancer: long-term ...
ADT can normalize serum prostate specific antigen in over 90% of patients and results in sizable tumor response in 80% to 90%. This treatment can be done either ...
Short-term Androgen Deprivation Therapy and High-dose ...
Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer. At median follow- ...
Adverse health outcomes for prostate cancer patients ...
Overall, 43% (PCa patients) and 20% (controls) reported major sexual problems. In patients aged < 75 years, longer than short ADT duration ...
a systematic review and network meta-analysis - PMC
This systematic review and network meta-analysis aimed to assess the comparative effectiveness and safety profiles of current combination therapies based on ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.